These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15717032)

  • 1. FDA: evidentiary standards for drug development and approval.
    Katz R
    NeuroRx; 2004 Jul; 1(3):307-16. PubMed ID: 15717032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting.
    Phillips AT; Desai NR; Krumholz HM; Zou CX; Miller JE; Ross JS
    Trials; 2017 Jul; 18(1):333. PubMed ID: 28720112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA given new powers over data reporting to national clinical trials registry.
    Roehr B
    BMJ; 2012 Oct; 345():e6629. PubMed ID: 23033375
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of the fDA in cancer clinical trials.
    Hirschfeld S
    Cancer Treat Res; 2007; 132():51-109. PubMed ID: 17305017
    [No Abstract]   [Full Text] [Related]  

  • 7. Relocating abroad. FDA sends staff overseas to help monitor imports.
    Lee J
    Mod Healthc; 2011 Oct; 41(43):32. PubMed ID: 22111150
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA Amendments Act of 2007 - Assessing Its Effects a Decade Later.
    Avorn J; Kesselheim A; Sarpatwari A
    N Engl J Med; 2018 Sep; 379(12):1097-1099. PubMed ID: 30231220
    [No Abstract]   [Full Text] [Related]  

  • 9. Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.
    Vaduganathan M; Butler J; Gheorghiade M
    Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27707750
    [No Abstract]   [Full Text] [Related]  

  • 10. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape.
    Benda N; Brandt A
    J Biopharm Stat; 2018; 28(1):3-9. PubMed ID: 29065277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA and drug approval.
    Faich GA
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):24S. PubMed ID: 8770838
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer nanotherapeutics in clinical trials.
    Lytton-Jean AK; Kauffman KJ; Kaczmarek JC; Langer R
    Cancer Treat Res; 2015; 166():293-322. PubMed ID: 25895874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Congress responds to the IOM drug safety report--in full.
    Psaty BM; Korn D
    JAMA; 2007 Nov; 298(18):2185-7. PubMed ID: 18000202
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA oversight of cell therapy clinical trials.
    Au P; Hursh DA; Lim A; Moos MC; Oh SS; Schneider BS; Witten CM
    Sci Transl Med; 2012 Aug; 4(149):149fs31. PubMed ID: 22932219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 20. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.